Verastem (VSTM) Cash & Equivalents Growth (3y) (2014 - 2026)

Verastem (VSTM) Cash & Equivalents Growth (3y) (2014 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - 13.29%
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 10.63%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -16.07%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -8.88%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 47.78%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Verastem 607.94 Mn 410.11 Mn 15.90 Mn 23.16%

Historic Data

Download Data
DateValue
Mar 31, 2026 23.16%
Dec 31, 2025 37.37%
Sep 30, 2025 20.78%
Jun 30, 2025 36.97%
Mar 31, 2025 36.05%
Dec 31, 2024 5.90%
Sep 30, 2024 66.97%
Jun 30, 2024 49.46%
Mar 31, 2024 31.80%
Dec 31, 2023 4.75%
Sep 30, 2023 -17.71%
Jun 30, 2023 13.47%
Mar 31, 2023 -10.37%
Dec 31, 2022 22.03%
Sep 30, 2022 -8.88%
Jun 30, 2022 -17.30%
Mar 31, 2022 -20.10%
Dec 31, 2021 -16.80%
Sep 30, 2021 -42.92%
Jun 30, 2021 -47.10%